Pittsburgh, PA – According to filings with the U.S. Securities and Exchange Commission, Peptilogics is raising $35,777,098.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Jonathan Steckbeck played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Peptilogics

Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics. Through their computational platform, Peptilogics is radically altering drug discovery by not only uncovering new, previously unexplored chemical design space, but ensuring that each potential therapeutic is biologically viable and scalable to manufacture. Peptilogics’ lead clinical stage peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections, an unmet medical need. Our computational drug design platform connects and extracts insights from diverse biomedical data, allowing us to unlock a new universe of unexplored, novel peptides with powerful applications.

To learn more about Peptilogics, visit http://www.peptilogics.com/

Contact:
Jonathan Steckbeck, Chief Executive Officer
412-916-7207
https://www.linkedin.com/in/jsteckbeck/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved